MAPS Awards Grant for Pilot MDMA-assisted Massed Exposure Therapy Trial
27 août 2024 07h00 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS, which has incubated and funded cutting-edge psychedelic research for decades, is continuing to advance our understanding of psychedelic-assisted therapiesThis study is one of the first trials...
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application
09 août 2024 21h33 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
Three Pivotal Drug Policy Organizations Hold Media Briefing/Q&A on DEA Rescheduling of Cannabis
01 mai 2024 17h54 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
WASHINGTON, May 01, 2024 (GLOBE NEWSWIRE) -- What: The Multidisciplinary Association for Psychedelic Studies (MAPS), The Marijuana Policy Project (MPP), and the National Organization for the...
MAPS Provides Psychedelic Crisis Assessment and Intervention Training to Denver’s First Responders
11 mars 2024 11h50 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS uses its over 30 years of experience in the psychedelic space to offer a first-of-its-kind gold-standard training program.
MAPS Announces Celestial Plans for Its 38th Anniversary
07 mars 2024 12h34 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS, which celebrates its 38th anniversary on April 8, will celebrate with a total solar eclipse at the Texas Eclipse 2024 festival in Texas
Psychedelic Science 2025 – the Fifth and Largest Psychedelic Conference in History – Announced for June 16-20 2025 in Denver, Colorado
13 févr. 2024 13h29 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
SAN JOSE, Calif. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that the Psychedelic Science 2025 Conference will convene in the...
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
09 févr. 2024 19h30 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
16 janv. 2024 16h27 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movementCurrently, MAPS serves as a fiscal sponsor for 10 organizations in the newly...
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
05 janv. 2024 08h01 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS shares ownership of Lykos with mission-aligned investors, will continue to advance psychedelic research, change drug policy, and shape culture
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
13 déc. 2023 18h16 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS